The Life Sciences Report Examines How With Complet

SAN FRANCISCO, CA --(Marketwired - June 29, 2017) - A Canadian company with its lead drug candidate in a Phase 3 trial recently closed an offering that raised CA$10 million for future research, which has one analyst contemplating the potential.

Included in this article is: Resverlogix Corp. ( TSX : RVX )

Resverlogix Corp. is developing apabetalone (RVX-208) for treatment of major adverse cardiac events (MACE). The compound is currently in a Phase 3 trial, BETonMACE, treating diabetic patients with cardiovascular disease (CVD). The trial was initiated in 2015. "We believe the trial will take approximately 3 years to complete, targeting topline readout in 2018," John Vandermosten, an analyst with Zacks Small-Cap Research, wrote. "With a potential impact on multiple markers for CVD we are optimistic on a materially significant impact on MACE."

Vandermosten noted that, "The CAD$10 million capital raise should be sufficient to provide the flexibility to negotiate a larger licensing or first right of refusal deal that will support clinical trials and operations until a new drug application can be submitted to the FDA, which we anticipate occurring in 2019."

Continue reading this article: With Completion of Offer, Analyst Says This Biotech Stock Could Triple

About Streetwise Reports - The Life Sciences Report

Investors rely on The Life Sciences Report to share investment ideas for the biotech, pharmaceutical, medical device, and diagnostics industries. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.

DISCLOSURES:

The following company mentioned in this article is a billboard sponsor of Streetwise Reports: Resverlogix Corp. Streetwise Reports does not accept stock in exchange for its services. Click here for important disclosures about sponsor fees. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security. Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers.

Please see the end of the article for the complete disclosures: With Completion of Offer, Analyst Says This Biotech Stock Could Triple